Horizon to Acquire US Rights for VIMOVO from Pozen

POZEN

today announced that AstraZeneca AB

and Horizon Pharma USA, Inc.

have entered into an agreement for Horizon to acquire the U.S. rights for VIMOVO® (naproxen / esomeprazole magnesium) delayed release tablets. Under the terms of the agreement, POZEN will continue to receive a 10% royalty on Net Sales of products sold in the United States, with guaranteed annual minimum royalty payments of $5 million in 2014, and $7.5 million each year thereafter, provided that the patents owned by POZEN which cover VIMOVO® are in effect and no generic forms of VIMOVO® are on the market. Also under the agreement, Horizon has assumed AstraZeneca's right to lead the